Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. - Wikidata - awgldk - TriplyDB

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.

http://www.wikidata.org/entity/Q45030492

about

Interventions to improve vaginal health for reducing the risk of HIV acquisition Treatment for recurrent vulvovaginal candidiasis (thrush)Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis Studies of Immune Responses in Candida vaginitis NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.Recurrent vulvovaginal candidiasis.Candida infections of the genitourinary tract.Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms.Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.Microsatellite marker analysis as a typing system for Candida glabrata.Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists a Genital mycotic infections in patients with diabetes.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.The recurrent vulvovaginal candidiasis: proposal of a personalized therapeutic protocol Chronic vulvovaginal Candida hypersensitivity: An underrecognized and undertreated disorder by allergists Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection Practices of Lebanese gynecologists regarding treatment of recurrent vulvovaginal candidiasis Candida isolates from pregnant women and their antifungal susceptibility in a Malaysian tertiary-care hospital.Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis Anticandidal immunity and vaginitis: novel opportunities for immune intervention.An update on antifungal targets and mechanisms of resistance in Candida albicans.Recurrent vulvovaginal candidiasis: A review of guideline recommendations.Colonization by Candida species of the oral and vaginal mucosa in HIV-infected and noninfected women.Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine.The Comparison of vaginal cream of mixing yogurt, honey and clotrimazole on symptoms of vaginal candidiasis.Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013)Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women.Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis.Candida duobushaemulonii: an emerging rare pathogenic yeast isolated from recurrent vulvovaginal candidiasis in Brazil.In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal Candida albicans Isolates.Effect of beta-1,6-glucan inhibitors on the invasion process of Candida albicans: potential mechanism of their in vivo efficacy.NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis.Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model.Cervical mucins carry alpha(1,2)fucosylated glycans that partly protect from experimental vaginal candidiasis.

P2860

Q24198302-36A7EBB7-2DBE-4FAA-82D2-4B6BA43F2825 Q24234856-3E7E72F0-09F5-4E17-BAAE-BE8D025CE9AE Q24629644-BA772A10-D2A2-4E69-9218-869623F35E31 Q26782272-E4E6DBA3-EE43-4428-889A-1FB28A424E90 Q30528889-8E90D628-D189-41F7-A642-EA20D21E2695 Q33798920-FE962F52-F956-4212-B125-B302EBD77E20 Q33825621-3BF5E837-6A38-4500-AB81-E8D0FB8B5A08 Q33843060-3CC38E2C-8DEF-4858-B167-2A7D39C7A062 Q33859133-E0242F5B-FB84-40AE-8A32-E67D30A96E89 Q34004099-D33B6AB9-80A7-4FE5-BEB0-B17D27DF5179 Q34042191-37BF4238-E598-4355-82B7-AAFC87E0F693 Q34045468-30C6F3E1-4A70-40AA-BA4C-D2EE307D070B Q34123634-72A2F18B-6ACA-4328-B44D-E128F54E1E57 Q34269717-F8EB2D16-292E-4A1D-A937-8263F1E1C3C0 Q34349532-80A9DC16-B58F-4459-85B4-C6C1DA8487FA Q34505582-ED701D29-AD58-4428-9346-482F09A41851 Q35157622-54786526-83B4-4210-ACE6-F7821CC0C709 Q35306896-805A9AD1-585D-4E6F-B3F4-B3E48EB7DA2E Q35681666-6EEC1075-0318-4D34-AF5F-DCAC903D2F12 Q35731576-045DBD83-7B99-4341-BC4C-78A7258C511F Q35796817-74C7EBB9-A34B-4689-AF68-CF709F242D7B Q35960896-95B46B26-BD1C-4E7B-A1AF-43476CF114B7 Q36097307-ECDADA06-927A-4DB4-A312-05E20C5AD0A8 Q36235037-7967C051-A1E4-47B4-A551-C733B7744E3E Q36309993-1D13638F-9257-4E52-9152-ACCE357A0462 Q36509561-38A23741-9309-4B11-928F-4107DBEC2790 Q36690302-69AA5855-2501-49A1-92BA-CFF89BFC1409 Q36718267-F69D07BB-EC09-4E18-8963-85B006FF839B Q36743194-5D0AB652-AE4B-41BD-B421-5113246FFDFA Q36812845-2FEACCCA-0391-4804-8581-CCE9F79051A9 Q36850886-4ABDD298-7016-4EFE-B503-C4F615320DC4 Q37007553-3B0407BD-41CA-47BD-A0D6-315CEE81A761 Q37144780-F51C7E12-F136-4F33-9629-D0A1466066BC Q37274301-A6B6B25E-B331-41A8-9EEE-06410CE57A31 Q37287736-FA48484C-01F3-419E-B4D9-DB45D5BCEB1E Q37333084-6C73E972-F776-4228-9031-89D0757ED55E Q37399422-0D940C34-3998-4136-BF42-8237D5A39EC6 Q37407646-564724DC-A6A6-4EB4-B31D-0C242E68A7C9 Q37411685-6DE464DD-AE35-4581-BDFD-4ED7CAE0F855 Q37479984-421A6DAB-373D-4658-AF78-64B9E8FCA301

P2860

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.

http://www.wikidata.org/entity/Q45030492

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.

@en

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.

@nl

type

label

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.

@en

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.

@nl

prefLabel

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.

@en

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.

@nl

P1433

Q45030492-1572A0B9-C215-46C6-9BA5-763F0FB0EAA4

P1476

Q45030492-6A80C131-5AA8-48DB-A889-50C8C4E6FD5A

P2093

Q45030492-0F9B48F5-A7B2-4685-84B5-071D69C5F321

Q45030492-10412691-A4F4-4D52-B0F2-472CDF6D8E74

Q45030492-1808A939-F0ED-47C0-9FCC-94ABFC33EF7F

Q45030492-1A47A499-B3F3-49A0-B77F-6D461388D1FA

Q45030492-1DF3C11A-2184-4159-AD50-8EED3E21E06C

Q45030492-37F8F94B-39A8-48AB-956E-47071029362B

Q45030492-6766A508-57DD-4C39-A320-E65E314F8AFD

Q45030492-88986C98-9AD6-40F3-8C0A-1D2252A05723

Q45030492-8E8332A0-E1C6-4174-A2BD-6C31943E2831

Q45030492-95473066-AEC5-46B5-93BF-165287102D1E

P304

Q45030492-D973FDC6-2903-4D23-98E8-1EF95BBBFF06

P31

Q45030492-320A4B71-30B8-4D73-A697-0FD9380AFF1E

P356

Q45030492-74DF192E-386A-4438-86A3-7D3A0AD88D76

P407

Q45030492-5448F30D-0DD5-4623-BC0D-EE981C7F3279

P433

Q45030492-FE79268D-59C9-4B96-A093-D4EE1E5A3EB0

P478

Q45030492-ADFFAAD0-B177-4C99-B3D5-D10AFB8AD48E

P577

Q45030492-AEF89B0E-0149-40A5-86FD-00C28E1C4F43

P5875

Q45030492-2FD4CD83-C0F1-4208-9395-1B649EDF0201

P698

Q45030492-DCCFEEC0-58AE-4CA4-93F6-BB8B2AA2598A

P356

P1433

The New England Journal of Medicine

P1476

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.

@en

P2093

Anne Rompalo

http://www.w3.org/2001/XMLSchema#string

Benson Horowitz

http://www.w3.org/2001/XMLSchema#string

Charles Livengood

http://www.w3.org/2001/XMLSchema#string

Harold C Wiesenfeld

http://www.w3.org/2001/XMLSchema#string

Helene Panzer

http://www.w3.org/2001/XMLSchema#string

Jack D Sobel

http://www.w3.org/2001/XMLSchema#string

James Von Thron

http://www.w3.org/2001/XMLSchema#string

Libby Edwards

http://www.w3.org/2001/XMLSchema#string

Malcolm Sperling

http://www.w3.org/2001/XMLSchema#string

Mark Martens

http://www.w3.org/2001/XMLSchema#string

P304

876-883

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA033114

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

351

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8383603

http://www.w3.org/2001/XMLSchema#string

P698

15329425

http://www.w3.org/2001/XMLSchema#string